Naringenin inhibits migration of bladder cancer cells through downregulation of AKT and MMP-2

Molecular Medicine Reports

Volumn 10, Issue 3, 2014, Pages 1531-1536

  Liao, Alex Chien Hwa ^a,b   Kuo, Chia Cheng ^c   Huang, Yei Chung ^d   Yeh, Chi Wei ^d   Hseu, You Cheng ^e   Liu, Jer Yuh ^f,g   Hsu, Li Sung ^d,h  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c Department of Internal Medicine Buddhist Tzu Chi General Hospital   (China)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bladder cancer; Matrix metalloproteinase 2; Migration; Naringenin

Indexed keywords

GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NARINGENIN; PROTEIN KINASE B; UROKINASE; FLAVANONE DERIVATIVE; MMP2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; BLADDER CARCINOMA; CARCINOMA CELL; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN EXPRESSION; WESTERN BLOTTING; WOUND HEALING; ZYMOGRAPHY; BLADDER TUMOR; CELL MOTION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLAVANONES; HUMANS; MATRIX METALLOPROTEINASE 2; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84905502744     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2375     Document Type: Article

References (21)

1. Tian B, Wang Z, Zhao Y, et al: Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett 264: 299-308, 2008.
2. Sun F, Zheng XY, Ye J, Wu TT, Wang JI and Chen W: Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 64: 599-606, 2012.
3. Zhang L, Chen W and Li X: A novel anticancer effect of butein: inhibition of invasion through the ERK1/2 and NF-kappaB signaling pathways in bladder cancer cells. FEBS Lett 582: 1821-1828, 2008.
4. Chen NG, Lu CC, Lin YH, et al: Proteomic approaches to study epigallocatechin gallate-provoked apoptosis of TSGH-8301 human urinary bladder carcinoma cells: roles of AKT and heat shock protein 27-modulated intrinsic apoptotic pathways. Oncol Rep 26: 939-947, 2011.
5. Qin J, Wang Y, Bai Y, et al: Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via suppression of NF-κB mediated matrix metalloproteinase-9 expression. Mol Med Rep 6: 1040-1044, 2012.
6. Frydoonfar HR, McGrath DR and Spigelman AD: The variable effect on proliferation of a colon cancer cell line by the citrus fruit flavonoid Naringenin. Colorectal Dis 5: 149-152, 2003. (Pubitemid 36442837)
7. Lentini A, Forni C, Provenzano B and Beninati S: Enhancement of transglutaminase activity and polyamine depletion in B16-F10 melanoma cells by flavonoids naringenin and hesperitin correlate to reduction of the in vivo metastatic potential. Amino Acids 32: 95-100, 2007. (Pubitemid 44866573)
8. Subramanian P and Arul D: Attenuation of NDEA-induced hepatocarcinogenesis by naringenin in rats. Cell Biochem Funct 31: 511-517, 2013.
9. Chen S, Ding Y, Tao W, Zhang W, Liang T and Liu C: Naringenin inhibits TNF-α induced VSMC proliferation and migration via induction of HO-1. Food Chem Toxicol 50: 3025-3031, 2012.
10. Lou C, Zhang F, Yang M, et al: Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS One 7: e50956, 2012.
11. Kim JJ: Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep 13: 147-152, 2012.
12. Min C, Eddy SF, Sherr DH and Sonenshein GE: NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem 104: 733-744, 2008. (Pubitemid 351830825)
13. Klein T and Bischoff R: Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41: 271-290, 2011.
14. Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27, 2011.
15. Kawabata K, Murakami A and Ohigashi H: Nobiletin, a citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells. Biosci Biotechnol Biochem 69: 307-314, 2005. (Pubitemid 40413251)
16. Baek SH, Kim SM, Nam D, et al: Antimetastatic effect of nobiletin through the down-regulation of CXC chemokine receptor type 4 and matrix metallopeptidase-9. Pharm Biol 50: 1210-1218, 2012.
17. Luqman S and Pezzuto JM: NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res 24: 949-963, 2010.
18. Sheng S, Qiao M and Pardee AB: Metastasis and AKT activation. J Cell Physiol 218: 451-454, 2009.
19. Cicenas J: The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 23: 1-9, 2008.
20. Lee YC, Cheng TH, Lee JS, et al: Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/PI3K/Akt and small GTPase signals in human gastric adenocarcinoma AGS cells. Mol Cell Biochem 347: 103-115, 2011.
21. Chien CS, Shen KH, Huang JS, Ko SC and Shih YW: Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem 333: 169-180, 2010.